Most tumors were T1c (40.8%), invasive ductal carcinoma (IDC; 84.1%), histologic grade 2 (49.9%), without lymphovascular invasion (81%), estrogen (ER; 86.1%), progesterone receptor-positive (PR;80.2%), and without HER2 overexpression (88.5%) (Table 1). This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.